Big Pharma

Premium

Though Big Pharma Remains LukeWarm on Genomics, Genotypers May See Respite First

R&D budgets at big pharma are expected to continue expanding into 2004 and beyond, but that doesn’t mean these firms will invest in new genomic tools or services any time soon, according to a recent panel discussion.

But genotyping instruments and services, largely because of their proximity to clinical trials and a wide appreciation of their potential application in personalized medicine, may emerge from the current market slump ahead of other genomic disciplines.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.